# Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

> **NCT07756294** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Insulin
- **DRUG:** Insulin Placebo
- **DRUG:** Empagliflozin Placebo

## Key facts

- **NCT ID:** NCT07756294
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07756294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07756294, "Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07756294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*